Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
Kyverna Therapeutics (Nasdaq: KYTX) announced management will attend investor conferences in March 2026, including a Leerink fireside chat and Jefferies investor meetings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kyverna Therapeutics (Nasdaq: KYTX) announced management will attend investor conferences in March 2026, including a Leerink fireside chat and Jefferies investor meetings.
The Leerink fireside chat is scheduled for March 9, 2026 at 11:20 a.m. ET; a live webcast and a 90-day replay will be available via the company investor website, according to the company.
Details
News Market Reaction – KYTX
On Mar 3, the day this news came out, KYTX closed 5.76% below the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- Leerink conference date
- March 9, 2026
- Leerink Partners 2026 Global Healthcare Conference
- Leerink conference time
- 11:20 a.m. ET
- Scheduled time for fireside chat
- Jefferies summit date
- March 10, 2026
- 2026 Jefferies Biotech on the Beach Summit
- Webcast replay window
- 90 days
- Leerink fireside chat replay availability on company website
Historical Context
-
Two experienced biotech leaders appointed to strengthen board oversight.
-
New CTO with long cell and gene therapy manufacturing background.
-
BLA timing, Phase 3 enrollment, IND acceptance and cash runway details.
-
Planned presentation at major healthcare conference with webcast access.
-
Pricing of $100M public offering of common stock at $7.50 per share.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced that company management will participate in the following upcoming conferences:
Leerink Partners 2026 Global Healthcare Conference
Format: Fireside chat and investor meetings
Date: Monday, March 9th, 2026
Time: 11:20 a.m. ET
2026 Jefferies Biotech on the Beach Summit
Format: Investor meetings
Date: Tuesday, March 10th, 2026
A live webcast of the Leerink fireside chat may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 90 days following the conference.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating autoimmune patients through the curative potential of cell therapy. The Company’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its initial indications in stiff person syndrome and myasthenia gravis. The Company is also advancing additional clinical and investigator-sponsored studies, including in multiple sclerosis and rheumatoid arthritis, to inform future priority indications and develop next-generation CAR T platforms to improve access and patient experience. For more information, please visit https://kyvernatx.com.
Contacts:
Investors: InvestorRelations@kyvernatx.com
Media: media@kyvernatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.